PPDA
Biological Activity
Subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D-containing receptors (Ki values are 0.096, 0.125, 0.31 and 0.55 μM for NR2C, NR2D, NR2B and NR2A subunits respectively).
Licensing Information
Sold under license from UNeMed Corporation.
Technical Data
| M. Wt | 378.38 |
| Formula | C21H18N2O5 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 684283-16-7 |
| PubChem ID | 90488770 |
| InChI Key | FAQARVDXAFZICA-QVUSPSOHSA-N |
| Smiles | O=C(C2=CC=C3C(C=CC4=C3C=CC=C4)=C2)N1[C@@H]([C@](O)=O)[C@@H]([C@](O)=O)NCC1.O=C(C6=CC=C7C(C=CC8=C7C=CC=C8)=C6)N5[C@H](C(O)=O)[C@H](C(O)=O)NCC5 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| 2eq. NaOH | 18.92 | 50 | |
| DMSO | 37.84 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 378.38. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.64 mL | 13.21 mL | 26.43 mL |
| 5 mM | 0.53 mL | 2.64 mL | 5.29 mL |
| 10 mM | 0.26 mL | 1.32 mL | 2.64 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.53 mL |
Molarity Calculator
Reconstitution Calculator
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Feng et al (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br.J.Pharmacol. 141 508 PMID: 14718249
Morley et al (2005) Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J.Med.Chem. 48 2627 PMID: 15801853
Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-methyl-D-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066 PMID: 15743930
If you know of a relevant reference for PPDA, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PPDA, supplier, Subtype-selective, NR2C/NR2D, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, cis-ppda, NMDA, Receptors, Tocris Bioscience
2 Citations for PPDA
Citations are publications that use Tocris products. Selected citations for PPDA include:
Mirante et al (2014) Distinct molecular components for thalamic- and cortical-dependent plasticity in the lateral amygdala. Autophagy 7 62 PMID: 25071439
Ferando and Mody (2013) Altered gamma oscillations during pregnancy through loss of δ subunit-containing GABA(A) receptors on parvalbumin interneurons. Front Neural Circuits 7 144 PMID: 24062647
Do you know of a great paper that uses PPDA from Tocris? If so please let us know.
Literature in this Area
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia PosterNew
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
